Cited by 55Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchProtein Kinase Regulation and GTPase Signaling

Pyk2 Signaling through Graf1 and RhoA GTPase Is Required for Amyloid-β Oligomer-Triggered Synapse Loss

Open access
Lee, Suho, Salazar, Santiago V., Cox, Timothy O., Strittmatter, Stephen M.·2019·The Journal of Neuroscience

Abstract

The intracellular tyrosine kinase Pyk2 (PTK2B) is related to focal adhesion kinase and localizes to postsynaptic sites in brain. Pyk2 genetic variation contributes to late onset Alzheimer's disease (AD) risk. We recently observed that Pyk2 is required for synapse loss and for learning deficits in a transgenic mouse model of AD. Here, we explore the cellular and biochemical basis for the action of Pyk2 tyrosine kinase in amyloid-β oligomer (Aβo)-induced dendritic spine loss. Overexpression of Pyk2 reduces dendritic spine density of hippocampal neurons by a kinase-dependent mechanism. Biochemical isolation of Pyk2-interacting proteins from brain identifies Graf1c, a RhoA GTPase-activating protein inhibited by Pyk2. Aβo-induced reductions in dendritic spine motility and chronic spine loss require both Pyk2 kinase and RhoA activation. Thus, Pyk2 functions at postsynaptic sites to modulate F-actin control by RhoA and regulate synapse maintenance of relevance to AD risk. SIGNIFICANCE STATEMENT Genetic variation at the Pyk2 locus is a risk for Alzheimer's disease. We have observed that Pyk2 is required for AD transgenic synapse loss and memory dysfunction. However, the cellular and biochemical basis for Pyk2 function related to AD is not defined. Here, we show that brain Pyk2 interacts with the RhoGAP protein Graf1 to alter dendritic spine stability via RhoA GTPase. Amyloid-β oligomer-induced dendritic spine loss requires the Pyk2/Graf1 pathway.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.2983-18.2018

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Oligomeric Aβ induces synaptic loss in neurons via Pyk2-mediated inactivation of the RhoGAP Graf1, leading to RhoA activation and subsequent dendritic spine retraction.

    “Oligomeric Aβ was found to induce synaptic loss in neurons via Pyk2-mediated inactivation of the RhoGAP Graf1, leading to RhoA activation and subsequent dendritic spine retraction [193].”

    From RhoA Signaling in Neurodegenerative Diseases (2022) · cites this paper as [193]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Salazar SV, Cox TO, Lee S, Brody AH, Chyung AS, Haas LT, Strittmatter SM (2018) Alzheimer's disease risk factor Pyk2 mediates amyloid-␤-induced synaptic dysfunction and loss. J Neurosci. Advance online publication. Retrieved December 5, 2018. doi: 10.1523/JNEUROSCI.1873-18.2018. · DOI · Paper page

Cited by

Sorted by citations

Authors
Lee, S., Salazar, S. V., Cox, T. O., & Strittmatter, S. M.
Affiliations
Yale University (US)
Venue
The Journal of Neuroscience
Published
2019-01-09
Volume
39
Issue
10
Pages
1910-1929
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2909808142
Cited by
55
References
9
Citations by year
2026: 8 · 2025: 6 · 2024: 4 · 2023: 7 · 2022: 10 · 2021: 8 · 2020: 11 · 2019: 1
FWCI
5.03
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (RF1AG053000, P50AG047270, R01AG034924)
  • National Institute of Neurological Disorders and Stroke (R35NS097283)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
Pyk2, RhoA, amyloid-beta oligomers, dendritic spine loss, synaptic loss, Alzheimer's disease, RhoGAP, postsynaptic signaling, hippocampal neurons, tyrosine kinase
MeSH terms
Animals, Female, Hippocampus, Humans, Male, Mice, Inbred C57BL, Synapses, Signal Transduction, Amyloid beta-Peptides, Mice, Knockout, GTPase-Activating Proteins, rhoA GTP-Binding Protein, Dendritic Spines, Focal Adhesion Kinase 2, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review